Investing Profile

Kevin Bitterman

InvestorVC

Partner at Polaris Partners

atlasventure.comCambridge, Massachusetts

Your Intro Paths to Kevin Bitterman

Signal uses Gmail to reveal intro paths. Email content is never read.

Networks Kevin is a member of

Rutgers University Network

69 CONNECTIONS

Rutgers University Network

69 CONNECTIONS

Harvard Medical School Network

64 CONNECTIONS

Atlas Venture Network

37 CONNECTIONS

Polaris Partners Network

30 CONNECTIONS

Find Kevin Bitterman on

Current Investing Position

Polaris Partners Partner

Investment Range

$10.0M - $50.0M

Sweet Spot

$25.0M

Investments On Record

Current Fund Size

$4B

Kevin Bitterman is on these Sector & Stage Rankings

Pharmaceuticals (Seed)BioTech (Seed)Pharmaceuticals (Series A)BioTech (Series A)Health IT (Series A)Health & Hospital Services (Series A)Boston / New England Health IT (Seed)Digital Health (Series A)Digital Health (Seed)Health & Hospital Services (Seed)

Kevin Bitterman's Investments On Record (18)

Company	StageDateRound Size	Total Raised
Renasant Bio	SeedJul 2025$55M	$55M
Co-investors: Deborah Palestrant (5am Ventures)
Judo Bio	Series AOct 2024$75M SeedNov 2023$25M	$100M
Co-investors: Jeff Goater (The Column Group), Steven Robinette (Atlas Venture)
GRO Biosciences	Series BJul 2024$60M	$91M
Co-investors: Ameena El-Bibany (Artis Ventures (AV)), Russ Wilcox (Pillar VC), Geoffrey Smith (Digitalis Ventures), Dror Berman (Innovation Endeavors), Dan Becker (Access Industries)
Disc Medicine	Post Ipo EquityJun 2024$180M Series AOct 2019$50M	$440M
Co-investors: Mark Chin (Jmi Equity), Mona Ashiya (OrbiMed Advisors)
Remix Therapeutics	Series UnknownJan 2024$60M Series BMay 2022$70M Series ADec 2020$65M SeedJan 2019$16M	$210M
Co-investors: Leon Chen (The Column Group), Kristina Burow (ARCH Venture Partners), Michael Rome (Foresite Capital), Peter Svennilson (The Column Group)
Mariana Oncology	Series BSep 2023$180M Series ADec 2021$75M	$250M
Co-investors: Dan Becker (Access Industries), Josh Resnick (Pure Imagination Brands), Geert-Jan Mulder (Forbion)
Curie Therapeutics	Series ADec 2021$75M	$75M
Co-investors: Dan Becker (Access Industries)
Akero Therapeutics	Series BDec 2018$70M Series AJun 2018$65M	$140M
Co-investors: Aaron Royston (venBio)

Kevin Bitterman's Experience

Board of Directors TARIS BiomedicalPresent

Board of Directors Visterra Inc.Present

Board of Directors KALA BIOPresent

Board of Directors Kala PharmaceuticalsPresent

Board of Directors Neuronetics, Inc.Present

Board of Directors Vets First ChoicePresent

Board Member New England Venture Capital AssociationPresent

Board of Directors Editas MedicinePresent

Board of Directors Morphic TherapeuticPresent

Member Board of Trustees Isabella Stewart Gardner MuseumPresent

Advisory Board Member Isabella Stewart Gardner MuseumPresent

Board of Directors Navitor PharmaceuticalsPresent

Board Of Directors Disc MedicinePresent

Board of Directors Akero TherapeuticsPresent

Board of Directors Remix TherapeuticsPresent

Board of Directors Kinaset TherapeuticsPresent

Board of Directors nChroma BioPresent

Board Chair Chroma MedicinePresent

Board of Directors Mariana OncologyPresent

Board of Directors Judo BioPresent

Partner Polaris PartnersPresent

Partner Polaris Venture PartnersPresent

Founding CEO Editas MedicinePresent

Founding CEO Morphic TherapeuticPresent

Partner Atlas VenturePresent

Kevin Bitterman's Education

Rutgers University – Camden BA Biology

Rutgers University BA BA, Biology

Rutgers University BA Biology

Harvard Medical School Ph.D. Genetics

Investors who invest with Kevin Bitterman

Scouts & Angels Affiliated With Kevin Bitterman